---

In the first quarter of 2024, Indivior PLC reported a notable performance with a 12% increase in total net revenue, reaching $284 million. This growth is spearheaded by SUBLOCADE®, which saw a remarkable 36% revenue increase compared to Q1 2023. The company has reconfirmed its FY 2024 guidance, anticipating accelerated net revenue and adjusted operating profit through the year.

---

Indivior’s Q1 results demonstrate robust financial health, underscored by double-digit revenue growth. Key drivers include:

• Revenue Growth: A consistent upward trajectory in SUBLOCADE® sales, contributing significantly to a 12% year-over-year revenue increase.
• Profit Margins: Despite aggressive expansion, profit margins have remained stable, benefiting from efficient cost management and innovative product offerings.
• Cash Flow: Solid cash flow generation supports strategic initiatives and potential market expansions.

Risk Factors

Indivior has identified several risk factors that could impact future performance:

• Market Competition: Increasing competition in the pharmaceutical sector could pressure pricing and market share.
• Regulatory Challenges: Stringent regulations and potential legal challenges pose ongoing risks.
• Dependency on Key Products: Heavy reliance on SUBLOCADE® for revenue generation could be risky if market dynamics shift.

CEO Mark Crossley highlighted the sustained demand for SUBLOCADE® and the company’s agile response to market needs. Management is optimistic about maintaining momentum through strategic initiatives and innovations.

Investment Highlights

Indivior’s investment appeal lies in its:

• Market Position: Strong foothold in addiction treatment with SUBLOCADE®.
• Innovation: Continued investment in R&D to enhance product offerings and address unmet medical needs.
• Strategic Initiatives: Plans for a U.S. primary listing to access broader capital markets and enhance shareholder value.

Historical Performance Review

Analysis of past performance reveals:

• Growth Trends: Consistent revenue growth over the past five years, with a compounded annual growth rate (CAGR) of approximately 8%.
• Operational Efficiency: Improvements in production and distribution have enhanced operational efficiency and profitability.

Liquidity and Capital Resources

Indivior maintains a healthy balance sheet with adequate liquidity ratios and manageable debt levels. The strategic financial management supports both ongoing operations and future growth opportunities.

Significant Events and Milestones

The company announced intentions to seek shareholder approval for a U.S. primary listing—a strategic move aimed at enhancing global presence and investor base.

Outlook and Future Projections

Indivior expects to continue its growth trajectory in FY 2024, with projections of increased revenue and earnings driven by strong market demand and ongoing strategic initiatives.

Key Takeaways for Investors

Investors should note Indivior’s robust growth, strategic market positioning, and proactive management approach. The planned U.S. listing and ongoing innovations present potential upside, while operational reliance on key products and regulatory environments warrant careful monitoring.